Opinion - (2025) Volume 15, Issue 3
Received: 01-May-2025, Manuscript No. jccr-25-170753;
Editor assigned: 03-May-2025, Pre QC No. P-170753;
Reviewed: 15-May-2025, QC No. Q-170753;
Revised: 22-May-2025, Manuscript No. R-170753;
Published:
29-May-2025
, DOI: 10.37421-2165-7920.2025.15.1661
Citation: Shahril, Syed. “Autoimmune Signs in Blood Cancers Emphasis on Connective Tissue Disorders and Vasculitis.” J Clin Case Rep 15 (2025): 1661.
Copyright: © 2025 Shahril S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Autoimmune features in blood cancers often arise from immune dysregulation driven by abnormal lymphoid or myeloid proliferation. For example, Chronic Lymphocytic Leukemia (CLL) is frequently associated with autoimmune hemolytic anemia and immune thrombocytopenia, conditions that reflect aberrant antibody production. In parallel, patients with lymphoma may exhibit systemic autoimmune signs resembling connective tissue disorders such as systemic lupus erythematosus or rheumatoid arthritis. The immune system, originally designed to detect and eliminate malignant cells, paradoxically generates autoreactive clones and inflammatory mediators that damage host tissues. This duality complicates clinical interpretation, as autoimmune manifestations may precede cancer detection and lead to misdiagnosis. Recognition of these patterns is vital, as they may serve as early warning signs of an underlying hematologic malignancy [2].
Connective tissue disorders (CTDs) in the context of blood cancers demonstrate how immune dysregulation extends beyond the hematopoietic system. Symptoms such as arthralgia, myalgia, Raynaudâ??s phenomenon and sclerodermoid changes may be observed in patients with lymphoma or myeloma. In some cases, patients initially diagnosed with autoimmune rheumatic disease are later found to harbor an occult hematologic malignancy. This overlap underscores the importance of distinguishing paraneoplastic autoimmune syndromes from primary connective tissue disease. Pathophysiologically, malignant B-cells can secrete autoantibodies, cytokines and growth factors that perpetuate tissue inflammation and fibrosis. Clinical management becomes challenging, as immunosuppressive therapies used for CTDs may exacerbate cancer progression, whereas anticancer therapies may ameliorate or worsen autoimmune features. This delicate balance highlights the need for integrated hematologyâ??rheumatology approaches [3].
Vasculitis represents another significant autoimmune complication in blood cancers, with both small- and medium-vessel types being reported. Leukocytoclastic vasculitis, polyarteritis nodosaâ??like syndromes and giant cell arteritisâ??like presentations have been documented in patients with leukemia and lymphoma. These manifestations often reflect immune complex deposition, direct vascular infiltration by malignant cells, or aberrant T-cell activation. Clinically, vasculitis can present with cutaneous purpura, neuropathy, renal involvement, or systemic inflammatory signs that mimic primary vasculitic disorders. Misdiagnosis can delay cancer detection or lead to inappropriate treatments such as long-term corticosteroids without addressing the underlying malignancy. Importantly, some vasculitic presentations resolve upon successful chemotherapy, further confirming their paraneoplastic nature. Recognizing vasculitis as a paraneoplastic signal may guide clinicians toward earlier detection of hematologic malignancy [4].
The coexistence of autoimmune manifestations and blood cancers has significant therapeutic and prognostic implications. Targeted therapies such as rituximab, originally developed for B-cell malignancies, have proven effective in both controlling cancer and suppressing autoimmune activity, particularly in autoimmune cytopenias and vasculitis. Similarly, checkpoint inhibitors, while effective in some hematologic malignancies, can paradoxically trigger autoimmune flares resembling connective tissue disorders. This duality demonstrates how the immune system sits at the center of cancer pathogenesis and autoimmune disease. Prognostically, the presence of autoimmune features in blood cancers may indicate either an aggressive disease course or, paradoxically, an enhanced anti-tumor immune response, depending on the context. Therefore, careful monitoring, multidisciplinary care and tailored immunomodulation are essential for optimizing patient outcomes in this complex clinical intersection [5].
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Google Scholar Cross Ref Indexed at
Journal of Clinical Case Reports received 1345 citations as per Google Scholar report